Veranova is investing over $50 million to add bioconjugation development and cGMP manufacturing at its Devens, MA site, creating up to 70 jobs.
The expansion, set for June 2026, will support ADCs and other bioconjugates, addressing rising demand for US-based biomanufacturing.
It builds on Devens’ expertise in complex synthesis and linker-payload production.